ScreenerHero

MRVIMaravai LifeSciences Holdings, Inc.

NAS · US · Healthcare · Biotechnology · maravai.com
8.640USD+19.67%Mkt Cap: 3.20B $P/E: —

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.20B $
Enterprise Value1.53B $
Revenue (TTM)208.78M $
Gross Profit33.99M $
Net Income (TTM)-130.77M $
Revenue/Share1.429 USD
Last Price8.640 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees415
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-82.58
PEG—
EV/EBITDA-77.69
EV/Revenue7.35
P/S14.71
P/B5.78
EPS (TTM)-0.61
EPS (Forward)-0.10
52W Range
2.28097% of range8.870
52W High8.870 USD
52W Low2.280 USD
Profitability
Gross Margin18.30%
Oper. Margin-29.40%
EBITDA Margin-9.46%
Profit Margin-70.41%
ROE-61.58%
ROA-16.97%
Growth
Revenue Growth8.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-57.57M $
CapEx (TTM)13.15M $
FCF Margin-1.74%
FCF Yield-0.11%
Net Debt148.01M $
Net Debt/EBITDA-7.50
Balance Sheet
Debt/Equity1.72
Current Ratio4.05
Quick Ratio2.63
Book Value/Sh1.434 USD
Cash/Share0.4700 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.300 USD
Upside (mean)-15.5%
Target Range6.500 USD – 8.000 USD
$6.500-15.5% to mean$8.000
# Analysts5
Ownership
Shares Out.148.99M
Float114.25M
Insiders13.64%
Institutions96.63%
Short Interest
Short Ratio3.1d
Short % Float6.77%
Short % Out.5.71%
Shares Short8.51M
Short (prev mo.)8.81M
Technical
SMA 506.187 (+39.6%)
SMA 2004.235 (+104.0%)
Beta0.58
S&P 52W Chg18.16%
Avg Vol (30d)2.98M
Avg Vol (10d)4.64M
Technical Indicators
RSI (14)78.4
MACD0.1679
MACD Signal0.0361
MACD Hist.+0.1318
BB Upper7.851 USD
BB Middle6.484 USD
BB Lower5.118 USD
BB Width42.15%
ATR (14)0.5354 USD
Vol Ratio (20d)3.60x